Subscribe to our newsletter to receive the latest product updates and special offers

HomeNewsScreenerMapsGroupsPortfolioInsiderFuturesForexCryptoBacktestsElite
Theme 		Help

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Earnings

Review historical estimates and see whether a company has beaten or missed expectations.

MNOV

Medicinova Inc

Last Close
Jun 18 • 04:00PM ET
1.31
Dollar change
-0.02
Percentage change
-1.50 		%
Held by: VXF IWC DFAC AVSC Scroll to Statements
Index- P/E- EPS (ttm)-0.17 Insider Own5.24% Shs Outstand49.05M Perf Week-2.24%
Market Cap64.26M Forward P/E- EPS next Y-0.24 Insider Trans0.00% Shs Float46.48M Perf Month-7.75%
Income-8.41M PEG- EPS next Q-0.06 Inst Own18.55% Short Float0.29% Perf Quarter-0.76%
Sales1.00M P/S64.26 EPS this Y-35.29% Inst Trans-0.93% Short Ratio4.51 Perf Half Y-16.03%
Book/sh1.22 P/B1.07 EPS next Y-4.35% ROA-12.55% Short Interest0.14M Perf Year-44.26%
Cash/sh0.96 P/C1.36 EPS next 5Y20.00% ROE-13.18% 52W Range1.26 - 2.66 Perf YTD-12.67%
Dividend Est.- P/FCF- EPS past 5Y13.30% ROI-13.97% 52W High-50.75% Beta0.71
Dividend TTM- Quick Ratio19.07 Sales past 5Y-20.00% Gross Margin92.93% 52W Low3.97% ATR (14)0.06
Dividend Ex-Date- Current Ratio19.07 EPS Y/Y TTM38.19% Oper. Margin-1007.30% RSI (14)42.07 Volatility4.07% 4.24%
Employees13 Debt/Eq0.01 Sales Y/Y TTM-100.00% Profit Margin-840.85% Recom1.00 Target Price16.50
Option/ShortYes / Yes LT Debt/Eq0.01 EPS Q/Q5.55% Payout- Rel Volume0.53 Prev Close1.33
Sales Surprise- EPS Surprise-20.00% Sales Q/Q- EarningsMay 10 BMO Avg Volume30.09K Price1.31
SMA20-3.91% SMA50-6.05% SMA200-19.01% Trades Volume15,844 Change-1.50%
Date Action Analyst Rating Change Price Target Change
Mar-10-21Initiated Maxim Group Buy $15
Mar-25-19Resumed B. Riley FBR Buy $22
Mar-28-18Initiated B. Riley FBR, Inc. Buy $22
Apr-18-17Initiated Credit Suisse Outperform
Jan-04-13Reiterated Ladenburg Thalmann Buy $10.50 → $6
May-24-12Downgrade MLV & Co Buy → Hold
Oct-18-11Reiterated MLV Capital Buy $13 → $6
Jun-22-11Initiated Global Hunter Securities Buy $4
May-12-10Initiated Wedbush Outperform $13
Nov-12-08Reiterated Ladenburg Thalmann Buy $22 → $6
Show Previous Ratings
Jun-05-24 06:00AM
MediciNova Receives Notice of Allowance for New Patent Covering MN-166 (ibudilast) for the Prevention of Metastasis of Various Solid Cancer
(GlobeNewswire)
Jun-03-24 06:00AM
MediciNova Announces Data from Phase 1b/2a Clinical Trial of MN-166 (ibudilast) in Glioblastoma Patients at the American Society of Clinical Oncology (ASCO) Annual Meeting 2024
(GlobeNewswire) +8.09%
May-28-24 06:00AM
MediciNova Announces Two Poster Presentations at the 92nd EAS Congress 2024, the Annual Meeting of the European Atherosclerosis Society Regarding the Use of MN-001 (Tipelukast) for Cardiometabolic Conditions
(GlobeNewswire)
May-20-24 06:00AM
MediciNova Receives Notice of Allowance for New Patent Covering MN-166 (ibudilast) for the Prevention of Metastasis of Eye Cancer
(GlobeNewswire)
May-14-24 06:00AM
MediciNova Receives Notice of Allowance for New Patent Covering MN-166 (ibudilast) for the Treatment of Chlorine-Induced Acute Respiratory Distress Syndrome
(GlobeNewswire)
May-10-24 08:52AM
MNOV Stock Earnings: MediciNova Misses EPS for Q1 2024
(InvestorPlace)
May-09-24 07:45PM
MediciNova: Q1 Earnings Snapshot
(Associated Press Finance) +8.15%
May-07-24 06:00AM
MediciNova Receives Issue Notification for New Patent Covering Extended-Release Formulations of MN-166 (ibudilast)
(GlobeNewswire)
Apr-02-24 07:00PM
MediciNova Announces Abstract Regarding Results of a Clinical Trial of MN-166 (ibudilast) in Glioblastoma Accepted for Presentation at the 2024 American Society of Clinical Oncology Annual Meeting (2024 ASCO)
(GlobeNewswire)
Mar-26-24 07:00PM
MediciNova Receives a Notice of Allowance for a New Patent Covering MN-166 (ibudilast) for the Treatment of Macular Injury in Japan
(GlobeNewswire) +8.09%
Mar-20-24 07:00PM
MediciNova Announces Two Abstracts regarding MN-001 (tipelukast) and MN-002 Accepted for Presentation at the 92nd EAS 2024 Congress, the Annual Meeting of the European Atherosclerosis Society
(GlobeNewswire)
Mar-12-24 06:30AM
MediciNova Announces New Data and Results of MN-166 (ibudilast) in Chlorine Gas-induced Acute Lung Injury Presented at the 63rd Annual Meeting of the Society of Toxicology
(GlobeNewswire)
Jan-17-24 06:00AM
MediciNova Receives a Notice of Grant for a New Patent Covering MN-166 (ibudilast) for the Treatment of Macular Injury in China
(GlobeNewswire)
Dec-21-23 06:00PM
MediciNova Announces Abstract Regarding MN-166 (ibudilast) in Chlorine Gas-induced Lung Injury Accepted for Presentation at the 63rd Annual Meeting of the Society of Toxicology
(GlobeNewswire)
Dec-06-23 06:00PM
MediciNova Receives a Notice of Decision to Grant for a New Patent Covering MN-166 (ibudilast) for the Treatment of Progressive MS in Europe
(GlobeNewswire)
Nov-19-23 06:00PM
MediciNova Announces New Data and Results of a Phase 2 Clinical Trial of MN-166 (ibudilast) in Glioblastoma Presented at the 28th Annual Meeting of the Society for Neuro-Oncology
(GlobeNewswire)
Nov-10-23 09:57AM
MediciNova: Q3 Earnings Snapshot
(Associated Press Finance)
Oct-27-23 01:00AM
MediciNova's Collaborator Initiates Clinical Development of a Gene Therapy Product for the Treatment of Phenylketonuria
(GlobeNewswire)
Oct-10-23 07:00PM
MediciNova Receives a Notice of Allowance for a New Patent Covering the Combination of MN-166 (ibudilast) and Riluzole for the Treatment of Amyotrophic Lateral Sclerosis (ALS) in Canada
(GlobeNewswire)
Oct-04-23 07:00PM
MediciNova Receives Gene Therapy Milestone Payment
(GlobeNewswire)
Sep-29-23 09:11AM
MNOV: Positive Results for MN-166 in Chlorine Gas-Induced Acute Lung Injury Model
(Zacks)
Sep-27-23 07:00PM
MediciNova Announces Results of Studies under BARDA Contract to Develop MN 166 (ibudilast) as a Medical Countermeasure Against Chlorine Gas-induced Lung Injury
(GlobeNewswire)
Aug-21-23 08:00AM
MNOV: Expecting Data for MN-166 in GBM and Chlorine Gas-Induced Lung Injury
(Zacks)
Aug-17-23 07:00PM
MediciNova Announces Abstract Regarding MN-166 (ibudilast) in Glioblastoma Accepted for Presentation at the Annual Meeting of the Society for Neuro-Oncology
(GlobeNewswire) -6.63%
Aug-16-23 07:00PM
MediciNova Receives a Notice of Intention to Grant for a New Patent Covering MN-166 (ibudilast) for the Treatment of Macular Injury in Europe
(GlobeNewswire) +6.93%
Aug-15-23 07:00PM
MediciNova Receives a New Patent Covering MN-001 for the Treatment of Scleroderma and Systemic Sclerosis in Europe
(GlobeNewswire)
Aug-14-23 07:00PM
MediciNova Receives a Notice of Intention to Grant for a New Patent Covering MN-001 and MN-002 for the Treatment of Advanced NASH in Europe
(GlobeNewswire)
Aug-10-23 02:12PM
MediciNova: Q2 Earnings Snapshot
(AP Finance)
Jul-23-23 09:56AM
With 49% ownership, MediciNova, Inc. (NASDAQ:MNOV) has piqued the interest of institutional investors
(Simply Wall St.)
Jun-29-23 06:00AM
MediciNova Announces Presentation of Results from the Phase 2b Trial of MN-166 (ibudilast) in Alcohol Use Disorder at the 46th Annual Research Society on Alcohol (RSA) Scientific Meeting
(GlobeNewswire)
May-30-23 05:00AM
MNOV: Compelling Buying Opportunity in Differentiated Small-Cap Biotech
(Zacks Small Cap Research)
May-14-23 07:00PM
MediciNova Receives a Notice of Intention to Grant for a New Patent Covering MN-166 (ibudilast) for Patients with Microorganism Infection in Europe
(GlobeNewswire)
May-12-23 07:47PM
MediciNova: Q1 Earnings Snapshot
(AP Finance)
Apr-30-23 07:00PM
MediciNova Receives a Notice of Allowance for a New Patent Covering MN-001 for the Treatment of Advanced NASH in Canada
(GlobeNewswire)
Mar-22-23 11:19AM
We Think MediciNova (NASDAQ:MNOV) Can Afford To Drive Business Growth
(Simply Wall St.)
Mar-09-23 06:00PM
MediciNova Announces Additional Extension of BARDA Contract to Develop MN-166 (ibudilast) as a Medical Countermeasure Against Chlorine Gas-induced Lung Injury
(GlobeNewswire)
Feb-27-23 04:57AM
MNOV: Phase 1/2 Clinical Trial of MN-166 in GBM Fully Enrolled
(Zacks Small Cap Research)
Feb-20-23 06:00PM
MediciNova Announces New Data Regarding MN-166 (ibudilast) in Glioblastoma Tumor Tissue Analysis Presented at the 20th Annual World Congress of Society for Brain Mapping and Therapeutics
(GlobeNewswire)
Feb-08-23 06:00PM
MediciNova Announces Health Canada Grants Authorization to Commence Multi-arm Phase 2/3 Clinical Trial to Evaluate MN-166 (ibudilast) in Long COVID
(GlobeNewswire)
Jan-30-23 06:00PM
MediciNova Announces Completion of Enrollment in the Phase 2b Clinical Trial of MN 166 (ibudilast) in Alcohol Use Disorder
(GlobeNewswire)
Jan-12-23 06:00PM
MediciNova Announces Completion of Enrollment in the Phase 2 Clinical Trial Evaluating MN-166 (ibudilast) for Treatment of Recurrent and Newly Diagnosed Glioblastoma
(GlobeNewswire)
Jan-10-23 10:00PM
MediciNova Receives a Notice of Allowance for a New Patent Covering MN-001 and MN-002 for the Treatment of Scleroderma and Systemic Sclerosis in Canada
(GlobeNewswire)
Jan-09-23 10:00PM
MediciNova Receives a Notice of Allowance for a New Patent Covering MN-001 and MN-002 for the Treatment of Hypertriglyceridemia, Hypercholesterolemia, and Hyperlipoproteinemia in Brazil
(GlobeNewswire)
Jan-05-23 06:00PM
MediciNova to Meet with U.S. FDA to Discuss Clinical Development of a Parenteral Formulation of MN-166 (ibudilast)
(GlobeNewswire) +6.22%
Dec-06-22 06:00PM
MediciNova Announces Additional Positive Results Regarding the Effects of MN-001 (tipelukast) on Serum Lipid Panel in Type 2 Diabetes and NAFLD Patients Presented at IDF 2022 Congress, the Annual Meeting of the International Diabetes Federation
(GlobeNewswire)
Dec-05-22 06:00PM
MediciNova Announces Positive Results from Secondary Analysis of Phase 2 Trial of MN-166 (ibudilast) Published in The American Journal of Drug and Alcohol Abuse
(GlobeNewswire)
Nov-29-22 05:43PM
13 Best Biotech Penny Stocks To Buy Now
(Insider Monkey) -5.26%
Nov-18-22 05:40AM
MNOV: Well Financed to Get Through Tough Market Conditions
(Zacks Small Cap Research)
Oct-13-22 10:50AM
We Think MediciNova (NASDAQ:MNOV) Can Afford To Drive Business Growth
(Simply Wall St.)
Sep-15-22 07:00PM
MediciNova to Participate in the Lytham Partners Fall 2022 Investor Conference
(GlobeNewswire)
Sep-14-22 07:00PM
MediciNova Receives Issue Notification for a New Patent Covering MN-166 (ibudilast) for the Treatment of Glioblastoma
(GlobeNewswire)
09:03AM
MediciNova Poised To Receive Canadian Patents For Cholesterol Candidates
(Benzinga)
Sep-13-22 07:00PM
MediciNova Receives a Notice of Allowance for a New Patent Covering MN-001 and MN-002 for the Treatment of Hypertriglyceridemia, Hypercholesterolemia, and Hyperlipoproteinemia in Canada
(GlobeNewswire)
Aug-19-22 06:23AM
MNOV: Phase 2 Trial of MN-001 in NAFLD Patients with Type 2 Diabetes and Hypertriglyceridemia Underway
(Zacks Small Cap Research) -5.00%
Aug-16-22 06:30AM
MediciNova Reaches Agreement to Participate in Grant-Funded Clinical Trial to Evaluate MN-166 (ibudilast) for the Treatment of Long COVID
(GlobeNewswire)
Aug-09-22 07:00PM
MediciNova Announces MN-001 (tipelukast) Abstract regarding Improvement of Serum Lipid Panel in Type 2 Diabetes and NAFLD Patients Accepted for Presentation at the IDF 2022 Congress, the Annual Meeting of the International Diabetes Federation
(GlobeNewswire)
Jul-27-22 06:30AM
MediciNova Receives Notice of Allowance for New Patent Covering MN-001 and MN-002 for the Treatment of Fibrosis in Korea
(GlobeNewswire)
Jul-26-22 06:30AM
MediciNova Announces Initiation of a Phase 2 Trial of MN-001 (tipelukast) in NAFLD with Type 2 Diabetes Mellitus and Hypertriglyceridemia
(GlobeNewswire)
Jul-21-22 07:00PM
MediciNova Initiates Clinical Evaluation of a New Parenteral Formulation of MN-166 (ibudilast)
(GlobeNewswire)
Jun-29-22 07:00PM
MediciNova Announces Extension of BARDA Contract to Develop MN-166 (ibudilast) as a Medical Countermeasure Against Chlorine Gas-induced Lung Injury
(GlobeNewswire)
Jun-22-22 07:00PM
MediciNova Announces MN-001 (tipelukast) Research Collaboration with The Juntendo University School of Medicine in Tokyo, Japan
(GlobeNewswire)
Jun-13-22 06:35AM
MNOV: Positive Results for MN-166 (Ibudilast) in Patients at Risk of Acute Respiratory Distress Syndrome
(Zacks Small Cap Research)
Jun-08-22 09:05AM
MediciNova Posts Promising Data From COVID-19 Treatment Candidate
(Benzinga) +8.94%
06:30AM
MediciNova Announces Positive Top-Line Results from Phase 2 Clinical Trial of MN-166 (ibudilast) in Hospitalized COVID-19 Patients at Risk for Acute Respiratory Distress Syndrome
(GlobeNewswire)
May-25-22 06:10AM
MNOV: Plans for Phase 2 Study of MN-001 (tipelukast) in NAFLD Patients with Type 2 Diabetes and Hypertriglyceridemia
(Zacks Small Cap Research)
May-06-22 09:48AM
We're Not Very Worried About MediciNova's (NASDAQ:MNOV) Cash Burn Rate
(Simply Wall St.)
Apr-21-22 07:00PM
MediciNova to Participate in the B. Riley Neuro & Ophthalmology Conference
(GlobeNewswire)
Apr-20-22 07:00PM
MediciNova Announces Publication of MN-166 (ibudilast) Data regarding Prevention of Metastasis in Uveal Melanoma in Molecular Cancer Research
(GlobeNewswire)
Apr-12-22 11:00PM
MediciNova Announces Completion of Enrollment in the Phase 2 Clinical Trial of MN-166 (ibudilast) in Hospitalized COVID-19 Patients at Risk for Acute Respiratory Distress Syndrome
(GlobeNewswire)
Apr-11-22 06:30AM
MediciNova Announces Plans for a Phase 2 Trial of MN-001 (tipelukast) in NAFLD with Type 2 Diabetes Mellitus and Hypertriglyceridemia
(GlobeNewswire)
Apr-08-22 09:38AM
MediciNova's Alcohol Use Disorder Candidate Reduces Alcohol Craving, Odds Of Heavy Drinking
(Benzinga)
Apr-07-22 07:00PM
MediciNova Announces Secondary Analysis of Phase 2 Trial of MN-166 (ibudilast) in Alcohol Use Disorder Published in Alcoholism: Clinical and Experimental Research
(GlobeNewswire)
Apr-06-22 11:15AM
MNOV: Genzyme Patent Litigation Could Lead to Significant Payout
(Zacks Small Cap Research)
Mar-17-22 06:30AM
MediciNova Receives Notice of Allowance for New Patent Covering MN-001 and MN-002 for the Treatment of Advanced NASH in Korea
(GlobeNewswire)
Mar-15-22 06:30AM
MediciNova to Participate in the 2022 Virtual Growth Conference Presented by Maxim Group LLC and hosted by M-Vest
(GlobeNewswire)
Mar-01-22 05:20AM
MNOV: Ibudilast Identified as Promising Development Candidate in Alcohol Use Disorder and Degenerative Cervical Myelopathy
(Zacks Small Cap Research)
Feb-28-22 06:30AM
MediciNova Announces MN-166 (ibudilast) Identified as Potential Beneficial Pharmacotherapy for Treatment of Degenerative Cervical Myelopathy in Global Spine Journal
(GlobeNewswire)
Feb-22-22 06:30AM
MediciNova Announces MN-166 (ibudilast) Identified as Promising Pharmacotherapy for Alcohol Use Disorder in Drugs
(GlobeNewswire)
Feb-14-22 01:12PM
The past three years for MediciNova (NASDAQ:MNOV) investors has not been profitable
(Simply Wall St.)
Feb-01-22 06:30AM
MediciNova Receives a New Patent Covering MN-001 for the Treatment of Hypertriglyceridemia, Hypercholesterolemia, and Hyperlipoproteinemia in Korea
(GlobeNewswire)
Jan-31-22 06:30AM
MediciNova Receives a Notice of Allowance for a New Patent Covering MN-001 and MN-002 for Hepatic Ballooning in Canada
(GlobeNewswire) +6.61%
Jan-27-22 06:30AM
MediciNova Receives a Notice of Intention to Grant for a New Patent Covering MN-166 (ibudilast) for the Treatment of Alcohol Use Disorder in Europe
(GlobeNewswire) -5.06%
Jan-26-22 06:30AM
MediciNova Receives a Notice of Intention to Grant for a New Patent Covering MN-001 and MN-002 for Hepatic Ballooning in Europe
(GlobeNewswire)
Dec-13-21 06:30AM
MediciNova Receives Notice of Allowance for New Patent Covering MN-166 (ibudilast) for the Treatment of ALS
(GlobeNewswire)
Dec-10-21 06:30AM
MediciNova Announces MN-166 (ibudilast) Poster Presentation at the 32nd International Symposium on ALS/MND
(GlobeNewswire)
Nov-23-21 05:04AM
MNOV: Addition of MN-166 to PD-1 Treatment Extends Survival in Preclinical GBM Model
(Zacks Small Cap Research) +43.97%
Nov-22-21 06:30AM
MediciNova Announces New Data regarding MN-166 (ibudilast) in Glioblastoma Presented at the 26th Annual Meeting of the Society for Neuro-Oncology
(GlobeNewswire)
Nov-15-21 12:40PM
We Think MediciNova (NASDAQ:MNOV) Can Easily Afford To Drive Business Growth
(Simply Wall St.)
Nov-11-21 06:00PM
MediciNova Announces MN-001 (tipelukast) Data regarding Lipid Metabolism in NASH/NAFLD to be Presented at The Liver Meeting® 2021, the Annual Meeting of the American Association for the Study of Liver Diseases
(GlobeNewswire)
Nov-10-21 06:00PM
MediciNova Announces New Data regarding MN-166 (ibudilast) in Uveal Melanoma Presented at the CURE OM Global Science Meeting
(GlobeNewswire)
Nov-03-21 07:30PM
MediciNova Announces New Data regarding MN-166 (ibudilast) in Glioblastoma to be Presented at the Annual Meeting of the Society for Neuro-Oncology
(GlobeNewswire)
Oct-21-21 06:30AM
MediciNova Announces Abstract regarding the Mechanism by which MN-001 (tipelukast) Alters Triglyceride Metabolism Accepted for Presentation at the 19th International Symposium on Atherosclerosis (ISA2021)
(GlobeNewswire)
Sep-02-21 11:00PM
MediciNova to Participate in the Morgan Stanley 19th Annual Global Healthcare Conference
(GlobeNewswire)
Sep-01-21 06:30AM
MediciNova Announces MN-001 (tipelukast) Abstract regarding Lipid Metabolism in NASH/NAFLD Accepted for Presentation at The Liver Meeting® 2021, the Annual Meeting of the American Association for the Study of Liver Diseases
(GlobeNewswire) +5.63%
Aug-30-21 06:30AM
MediciNova Announces MN-166 (ibudilast) ALS Abstract Accepted for Presentation at the 32nd International Symposium on ALS/MND
(GlobeNewswire)
Aug-16-21 11:23AM
MediciNova (NASDAQ:MNOV) investors are sitting on a loss of 61% if they invested three years ago
(Simply Wall St.)
11:03AM
MNOV: Animal Trials Commence Testing MN-166 as an MCM
(Zacks Small Cap Research)
Aug-12-21 07:00PM
MediciNova Reports Second Quarter 2021 Financial Results and Business Update
(GlobeNewswire)
Jul-06-21 06:30AM
MediciNova Receives Notice of Allowance for New Patent Covering MN-166 (ibudilast) for the Treatment of Ophthalmic Disease
(GlobeNewswire)
Jun-29-21 06:30AM
MediciNova to Present at the Ladenburg Thalmann 2021 Virtual Healthcare Conference
(GlobeNewswire)
MediciNova, Inc. is a biopharmaceutical company, which engages in the acquisition and development of small molecule therapeutics for the treatment of diseases with unmet medical needs. The company was founded by Yuichi Iwaki on September 26, 2000, and is headquartered in La Jolla, CA.
open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR
affiliate • advertise • careers • toggle light mode • contact • privacy • help
do not sell my data • privacy settings
Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
Copyright © 2007-2024 FINVIZ.com. All Rights Reserved.